Trial Profile
A Phase IIa, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Antidepressant Effect and Onset of Effect of AZD6765 in Treatment-Resistant Major Depressive Disorder Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Lanicemine (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 17 Aug 2007 New trial record.